the aid library

LIST OPTIONS

Filter

4466

Guidelines for the treatment of human African trypanosomiasis
recommended

World Health Organization WHO (2024) C_WHO

The present guidelines incorporate all these changes, leading to a substantial reconfiguration of therapeutic choices for both disease forms. HAT is a serious, life-threatening disease and the efficacy of fexinidazole depends on swallowing the medicine after an appropriate intake of food as well as... more

External Link

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
recommended

Turkova, A.; G.H. Wills, E. Wobudeya, et al. (2022) C2

N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535 Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)

Download (355)

View PDF (471)

HIV and tuberculosis co-infection programmes

Avert Avert (2019) C2

People living with HIV who have a low CD4 count are at a much higher risk of falling ill from TB infection than HIV negative people. It is important to offer both HIV testing to TB patients and TB diagnosis in HIV patients. Early detection and effective treatment are essential to preventing TB... more

Download (355)

View PDF (541)

Standard Operating Procedures - Bacteriology

Indian Council of Medical Research (2015) C1

Antimicrobial Resistance Surveillance and Research Network | This manual describes well accepted methods to carry out drug susceptibility testing on important gram positive and gram negative clinically relevant bacteria. Methods of specimen collection, transport, culture, anti-microbial drug suscept... more

External Link

Methicillin-ResistantStaphylococcus aureus(MRSA):Prevalence and Antimicrobial Sensitivity Pattern among Patients—A Multicenter Study in Asmara, Eritrea

Yohaness Garoy E., Y. Berhane Gebreab, O. Okoth Achila et al. Hindawi (2018) C2

Methicillin-resistant Staphylococcus aureus(MRSA) strainsor multidrug-resistant S.aureus, initially described in 1960s,emerged in the last decade as a cause of nosocomial infections responsible for rapidly progressive, potential fatal diseases including life-threatening pneumonia, necrotizing fascii... more

External Link

The malaria testing and treatment landscape in Benin

Zinsou, C.; A. Bello Cherifath ACT Watch Group et al (2017) C1

Malar J (2017) 16:174 DOI 10.1186/s12936-017-1808-x Background: Since 2004, artemisinin-based combination therapy (ACT) has been the first-line treatment for uncomplicated malaria in Benin. In 2016, a medicine outlet survey was implemented to investigate the availability, price, and market share of... more

Download (245)

View PDF (292)

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Download (300)

View PDF (453)

The Importance of Pharmacovigilance

World Health Organization WHO (2020) C_WHO

The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug... more

Download (459)

View PDF (691)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (726)

View PDF (1570)

Management of severe malnutrition: a manual for physicians and other senior health workers

World Health Organization WHO (1999) C_WHO

This manual provides practical guidelines for the management of children with severe malnutrition. It seeks to promote the best available therapy so as to reduce the risk of death, shorten the length of time spent in hospital, and facilitate rehabilitation and full recovery. Emphasis is given to the... more

Download (280)

View PDF (314)

High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries

Bortone, B.; et al. (2021) CC

PlosOne January 20, 2021 https://doi.org/10.1371/journal.pone.0241899 Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antim... more

Download (255)

View PDF (231)

Management & Post-Exposure Prophylaxis of Potential HIV and Hepatitis B Exposure in Children, Adolescents & Adults Guidelines (South Africa)

Western Cape Government Health, South Africa (2019) C1

1PEP GUIDELINES | 2019 EDITION. The prevalence of both HIV and Hepatitis B is high in South Africa therefore there is a significant risk of acquiring these infections following exposure to infected material. Studies suggest that post- exposure prophylaxis (PEP) with highly active antiretroviral trea... more

Download (369)

View PDF (280)

Overview of the antimicrobial resistance surveillance systems for Ghana, Malawi, Nepal and Nigeria

Dacombe R., I. Bates, B. Gopul et al. Liverpool School of Tropical Medicine (2016) C2

This study addresses part of the Terms of Reference for a scoping report ‘An analysis of approaches to laboratory capacity strengthening for drug resistant infections in low and middle income countries’. It has been produced as a separate report because it is also very relevant for a second stud... more

External Link

Factors associated with tuberculosis treatment failure in the Central East Health region of Burkina Faso

Diallo A., D. L. Dahourou, T. T. E. Dah et al. Panafrican Med Jounal (2018) C2

Tuberculosis treatment failure results in increased risk of morbidity, drug resistance, transmission and mortality. There are few data about tuberculosis treatment outcomes in Burkina Faso. The current study investigated the factors associated with tuberculosis treatment failure in the central east ... more

Download (284)

View PDF (264)

The role of HIV viral suppression in improving individual health and reducing transmission

World Health Organisation (WHO) (2023) C_WHO

This policy brief describes key HIV viral load thresholds and the available viral load testing approaches for monitoring how well antiretroviral therapy is working for people living with HIV. It provides clarification for and elaborates upon the current treatment monitoring algorithm from the Consol... more

Download (480)

View PDF (514)

Management of a cholera epidemic
recommended

Médecins sans Frontières MSF (2018) C1

Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians. The document is a comprehensive guide for managing cholera epidemics, providing detailed protocols for prevention, outbreak investigation, treatment, and control mea... more

Download (316)

View PDF (463)

Cholera - Q & A - Fact Sheet

UN Children's Fund UNICEF (2019) CC

The Cholera Q&A Fact Sheet provides essential information about cholera, including its causes, symptoms, treatment, and prevention. Cholera is an acute diarrheal disease caused by Vibrio cholerae, which spreads through contaminated water and food. It leads to rapid dehydration and can be fatal if un... more

Download (263)

View PDF (265)

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I... more

External Link

Optimal timing of HIV home‐based counselling and testing rounds in Western Kenya

Olney, Jack J.; Eaton, Jeffrey W.; Braitstein, Paula et al. (2018) CC

Journal of the International AIDS Society, vol. 21 Issue no. 6 e 25142
Weaknesses in care programmes providing anti‐retroviral therapy (ART) persist and are often instigated by late HIV diagnosis and poor linkage to care. We investigated the potential for a home‐based counselling and testin... more

Guidelines for the treatment of human African trypanosomiasis recommended

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children recommended

Management of a cholera epidemic recommended

Guidelines for the treatment of human African trypanosomiasis
recommended

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
recommended

Management of a cholera epidemic
recommended